Epanova® (omega-3 carboxylic acids) + corn oil control
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Conditions
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Trial Timeline
Oct 30, 2014 → May 27, 2020
NCT ID
NCT02104817About Epanova® (omega-3 carboxylic acids) + corn oil control
Epanova® (omega-3 carboxylic acids) + corn oil control is a phase 3 stage product being developed by AstraZeneca for Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD). The current trial status is completed. This product is registered under clinical trial identifier NCT02104817. Target conditions include Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02104817 | Phase 3 | Completed |